Biotech · Private company
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Track this companyFree. Adds Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA to your Dealase workspace and tells you when its record changes.
Clinical trials112 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- EnsifentrinePhase 3 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ensifentrine 3 mg twice dailyPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- EnsifentrinePhase 2 · Pulmonary Disease, Chronic Obstructive, COPDClinicalTrials.gov · fetched Nov 12, 2026
- Ensifentrine 1.5 mgPhase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ensifentrine 3 mgPhase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ensifentrine 3 mg (marketed formulation)Phase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Glycopyrrolate (14 μg)Phase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Glycopyrrolate (42.5 μg)Phase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Glycopyrrolate (85 μg)Phase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Glycopyrrolate 21.25 mcgPhase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Glycopyrrolate 42.5 mcgPhase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LABA/LAMAPhase 2 · Pulmonary Disease, Chronic Obstructive, COPDClinicalTrials.gov · fetched Nov 12, 2026
- Nebulized Ensifentrine Suspension; 3 mgPhase 2 · Non-cystic Fibrosis BronchiectasisClinicalTrials.gov · fetched Nov 12, 2026
- Part A: RPL554Phase 2 · Pulmonary Disease, Chronic ObstructiveClinicalTrials.gov · fetched Nov 12, 2026
- Part B: RPL554Phase 2 · Pulmonary Disease, Chronic ObstructiveClinicalTrials.gov · fetched Nov 12, 2026
- RPL554 SuspensionPhase 2 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- Tiotropium/olodaterol (Respimat)Phase 2 · COPDClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseasePHASE2 · COMPLETED · started Oct 6, 2025ClinicalTrials.gov NCT07132983 · fetched Nov 12, 2026
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)PHASE2 · COMPLETED · started Jul 31, 2025ClinicalTrials.gov NCT07016412 · fetched Nov 12, 2026
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisPHASE2 · RECRUITING · started Sep 11, 2024ClinicalTrials.gov NCT06559150 · fetched Nov 12, 2026
- A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDPHASE2 · COMPLETED · started Aug 16, 2024ClinicalTrials.gov NCT06545500 · fetched Nov 12, 2026
- Effect of Ensifentrine Treatment on CAT ScorePHASE3 · COMPLETED · started Jun 11, 2024ClinicalTrials.gov NCT06460493 · fetched Nov 12, 2026
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)PHASE2 · ACTIVE_NOT_RECRUITING · started May 27, 2022ClinicalTrials.gov NCT05270525 · fetched Nov 12, 2026
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDPHASE3 · COMPLETED · started Sep 29, 2020ClinicalTrials.gov NCT04535986 · fetched Nov 12, 2026
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDPHASE3 · COMPLETED · started Sep 22, 2020ClinicalTrials.gov NCT04542057 · fetched Nov 12, 2026
- Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDPHASE2 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03937479 · fetched Nov 12, 2026
- Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder InhalerPHASE2 · COMPLETED · started Dec 10, 2018ClinicalTrials.gov NCT04027439 · fetched Nov 12, 2026
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDPHASE2 · COMPLETED · started Jul 16, 2018ClinicalTrials.gov NCT03673670 · fetched Nov 12, 2026